Evidence Level
Chromium supplementation has been extensively studied for its potential benefits in blood sugar management and other health outcomes. A comprehensive meta-analysis by Balk et al. (2007) reviewed 41 randomized controlled trials (RCTs) and found modest improvements in glycemic control among individuals with type 2 diabetes, particularly at doses of 200-1,000mcg chromium picolinate. The Anderson et al. (1997) study remains a key reference, demonstrating significant reductions in HbA1c levels with 1,000mcg/day supplementation in Chinese participants.
Recent studies have explored additional effects of chromium. Hamsho et al. (2025) conducted a systematic review and meta-analysis of 10 RCTs involving 683 women with polycystic ovarian syndrome (PCOS), finding that chromium supplementation significantly improved biochemical parameters, outperforming metformin for some outcomes. However, Vajdi et al. (2024) reviewed 14 RCTs and found no significant effect of chromium on body composition metrics in type 2 diabetes patients. Similarly, Vajdi et al. (2023) conducted an umbrella review of eight studies and concluded that chromium supplementation had no meaningful impact on lipid profiles, including triglycerides, total cholesterol, LDL-C, or HDL-C levels.
Despite these findings, the American Diabetes Association does not recommend routine chromium supplementation due to inconsistent trial results. Additionally, while some studies suggest potential benefits in specific populations, others indicate limited efficacy for weight loss and lipid management. Overall, chromium's role remains context-dependent, with evidence supporting its use primarily in blood sugar management within certain dosage ranges.